Acorda Therapeutics, Inc. (NASDAQ:ACOR) reported Q2 2017 earnings this Morning, coming in at $0.29 per share, missing Wall Street’s estimates of $0.49 per Share. Revenue for the quarter came in at $139.40 million missing the streets estimates of $139.81 million
Analyst Coverage For Acorda Therapeutics, Inc. (NASDAQ:ACOR)
These are 6 Hold Ratings, 3 Buy Ratings .
The current consensus rating for Acorda Therapeutics, Inc. (NASDAQ:ACOR) is Hold (Score: 2.33) with a consensus target price of $24.67 , a potential (9.39% upside)Recent Insider Trading for Acorda Therapeutics, Inc. (NASDAQ:ACOR)
- On 6/16/2017 Ron Cohen, Insider, bought 20,000 with an average share price of $16.95 per share and the total transaction amounting to $339,000.00.
- On 5/15/2017 Andrew A Hindman, Insider, sold 7,704 with an average share price of $15.75 per share and the total transaction amounting to $121,338.00.
- On 12/14/2016 Ron Cohen, Insider, sold 40,172 with an average share price of $20.75 per share and the total transaction amounting to $833,569.00.
- On 10/21/2016 Richard P Batycky, Insider, sold 2,063 with an average share price of $20.30 per share and the total transaction amounting to $41,878.90.
- On 10/7/2016 David Lawrence, Insider, sold 250 with an average share price of $20.82 per share and the total transaction amounting to $5,205.00.
- On 10/3/2016 Jane Wasman, Insider, sold 3,750 with an average share price of $20.78 per share and the total transaction amounting to $77,925.00.
Recent Trading for Acorda Therapeutics, Inc. (NASDAQ:ACOR) Shares of Acorda Therapeutics, Inc. closed the previous trading session at 22.60 up +0.05 0.22% with 629,078 shares trading hands.